Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 22, 2019
Pharmacy Choice - News - Drug Delivery Systems - January 22, 2019

Pharmacy News

 Drug Delivery Systems
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/22/18 - Acorda Therapeutics Announces FDA Approval of INBRIJA? (levodopa inhalation powder)
Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration approved INBRIJA? for intermittent treatment of OFF episodes in people with Parkinson s disease treated with carbidopa/levodopa. Robert Langer at Massachusetts Institute of Technology, through years of enormous perseverance and ingenuity by the entire Acorda t
12/22/18 - ADDING MULTIMEDIA Acorda Therapeutics Announces FDA Approval of INBRIJA? (levodopa inhalation powder)
Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration approved INBRIJA? for intermittent treatment of OFF episodes in people with Parkinson s disease treated with carbidopa/levodopa. Robert Langer at Massachusetts Institute of Technology, through years of enormous perseverance and ingenuity by the entire Acorda t
12/22/18 - AUROBINDO DRUG GETS USFDA NOD
Aurobindo Pharma of Hyderabad has received the final approval from the US Food and Drug Administration to manufacture and sell its generic version of potassium chloride extended release tablets.
12/22/18 - FDA approves first treatment for rare blood disease [Sudan Tribune]
The U.S. Food and Drug Administration today approved Elzonris infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients, two years of age and older. Prior to todays approval, there had been no FDA approved therapies for BPDCN. Many patients with BPDCN are unable to tolerate this intensive therapy
12/21/18 - ADDING MULTIMEDIA Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors ProAir Digihaler? (albuterol sulfate 117 mcg) Inhalation Powder
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved ProAir Digihaler? inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. This approval marks a.
12/21/18 - Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 417
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for AR101, an investigational biologic oral immunotherapy for the treatment of peanut allergy in children and...
12/21/18 - AstraZeneca - Bevespi Aerosphere approved in the EU for chronic obstructive pulmonary disease
Dr Colin Reisner, Head of Respiratory, Global Medicines Development, said:' Bevespi Aerosphere is already available to COPD patients in the US and other countries, and this approval means we can now bring this new medicine to patients in Europe. Dr Omar Usmani, Consultant Physician in Respiratory Medicine at the National Heart& Lung Institute, Impe
12/21/18 - AstraZeneca - Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer
AstraZeneca and Merck& Co., Inc., Kenilworth, N.J., US today announced positive results from the randomised, open-label, controlled, Phase III SOLO-3 trial of Lynparza tablets in 266 patients with relapsed ovarian cancer after two or more lines of treatment. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Office
12/21/18 - AstraZeneca and Merck - LYNPARZA Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
KENILWORTH- AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced positive results from the randomized, open-label, controlled, Phase 3 SOLO-3 trial of LYNPARZA tablets in 266 patients with relapsed ovarian cancer after two or more lines of treatment. The trial was conducted as a post-approval commitment in agree
12/21/18 - Blood pressure medication recalled due to ?unexpected impurity'
-A pharmaceutical company has issued a voluntary recall of blood pressure medication Thursday.According to the FDA, Torrent Pharmaceuticals Limited is voluntarily recalling two lots of Losartan potassium tablets, Medical officials say the medication is being recalled due to the detection of trace amounts of an "unexpected impurity" found in an acti
12/21/18 - CERENIS Therapeutics - Results of the Phase I study of repeated and increasing doses to assess CER-209 in NASH/NAFLD
Toulouse- CERENIS Therapeutics, an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, today announces the favorable results of the Phase I study o
12/21/18 - FDA approves first treatment for rare blood disease
The U.S. Food and Drug Administration today approved Elzonris infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients, two years of age and older. "Prior to today's approval, there had been no FDA approved therapies for BPDCN. Many patients with BPDCN are unable to tolerate this intensive ther
12/21/18 - Genmab Announces European Commission Approval of DARZALEX (daratumumab) Split Dosing Regimen [Arab Times (Kuwait)]
Copenhagen, Denmark; December 20, 2018 Genmab A/S announced today that the European Commission has granted marketing authorization for a split dosing regimen for DARZALEX. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab. We are hopeful that the availability of this more fle
12/21/18 - Genmab Announces European Commission Approval of DARZALEX Split Dosing Regimen
Copenhagen- Genmab A/S announced today that the European Commission has granted marketing authorization for a split dosing regimen for DARZALEX. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab. 'We are hopeful that the availability of this more flexible dosing option will m
12/21/18 - Global Biopharmaceutical Drug Delivery Device Technology Market 2018-2023 - Focus on New Innovations
The "World Market for Biopharmaceutical Drug Delivery Device Technology" report has been added to ResearchAndMarkets.com' s offering. The total market for biopharmaceutical drug delivery is very complex and shifting due to technological advancements. Microsphere Technology Targeted Technology Intracellular Delivery Technology MicroChip...
12/21/18 - Graft Delivery Devices Market with Current Trends Analysis, 2018-2027: Fact.MR has announced the addition of the Graft Delivery Devices Market Forecast, Trend Analysis & Competition Tracking - Global Review 2017 to 2027"report to their offering.
Rockville, MD 12/21/2018 With the advent of advanced tissue transplantation tools or graft delivery devices, frequency and efficiency of tissue transplantation surgeries have increased dramatically. Over half a million bone grafting procedures are performed annually in the United States and the count crosses two billion across the globe.
12/21/18 - Janssen Announces European Commission Approval of Darzalex Split Dosing Regimen
BEERSE- The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the European Commission has granted marketing authorisation to provide healthcare professionals with the option to split the first infusion of Darzalex over two consecutive days. 'We are committed to the development of new treatments, combinations, and formulation
12/21/18 - Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy
STAINES-UPON-THAMES, United Kingdom and ABINGDON, United Kingdom and BUFFALO, N.Y., Dec. 21, 2018/ PRNewswire/ Mallinckrodt plc, a leading global specialty pharmaceutical company, and NPXe Limited today confirmed enrollment of the first patient in the pivotal Phase 3 trial of Xenon Gas for Post Cardiac Arrest Syndrome. The study is expected to in
12/21/18 - Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin
DUBLIN- Nabriva Therapeutics plc, a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced the submission of two New Drug Applications to the U.S. Food and Drug Administration for the oral and intravenous formulations of lefamulin, a first-in-class,
12/21/18 - Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults [Sport360]
-Nabriva Therapeutics plc, a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced the submission of two New Drug Applications to the U.S. Food and Drug Administration for the oral and intravenous formulations of lefamulin, a first-in-class,...
12/21/18 - Needle Free Drug Delivery Devices Market: Reduced Risk of Injuries Due to Needle-Stick to Fuel Market Development
Albany, NY 12/21/2018 The global Needle Free Drug Delivery Devices Market is anticipated to grow significantly over forecast period from 2015 to 2023. Antares Pharma Inc., Injex Pharma AG, Zogenix Inc., Glide Pharmaceutical Technologies Ltd., Pharmajet Inc., and 3 M are among the key players dominating the global needle free drug delivery dev
12/21/18 - Pharmaceutical Excipients Market Worldwide Analysis | Geographic Overview, Foremost Players, Segments, Size, Share and Foreseen to 2027
Global "Pharmaceutical Excipients Market" report is made by executing an Excellent research process to Gather information of Global Pharmaceutical Excipients Market and cover the other information such as Pharmaceutical Excipients Market Growth, Eminent players, chapter-wise Description followed by various user perceptions. According to a new...
12/21/18 - Polymer Chameleons Market to 2023: Industry Insights, Company Overview and Investment Analysis
"Polymer Chameleons Market" Polymer Chameleons Market size was estimated at278 million in 2016 which is expected to increase USD 278 million by the end of 2022, market is boosted due various industries such as Smart Drug Delivery System-Implants, Bioseparation, Textile engineering. The global Polymer Chameleon Market is expected to reach USD 1.59 b
12/21/18 - Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors ProAir Digihaler? (albuterol sulfate 117 mcg) Inhalation Powder
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved ProAir Digihaler? inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. This approval marks a.
12/21/18 - Transdermal Drug Delivery System Market Global Industry Scenario, Region Wise Growth, Trends, Size and to 2025 Forecast
Global Transdermal Drug Delivery System Market 2019 Research Reportisbriefoverview on Transdermal Drug Delivery System industry having detailed focus on major factors ofworldwidemarket for future pros...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415